Azacitidine and the beginnings of therapeutic epigenetic modulation.

Article Details

Citation

Copy to clipboard

O'Dwyer K, Maslak P

Azacitidine and the beginnings of therapeutic epigenetic modulation.

Expert Opin Pharmacother. 2008 Aug;9(11):1981-6. doi: 10.1517/14656566.9.11.1981 .

PubMed ID

18627335 [ View in PubMed

]

Abstract

BACKGROUND: Although originally developed as a cytarabine analog more than 40 years ago, azacitidine has been the subject of renewed interest in the era of cancer epigenetics. OBJECTIVE: What is the history of the clinical development of azacitidine and how has it been applied successfully to the treatment of myelodysplastic syndromes (MDS)? METHODS: We review the evolution of the use of azacitidine for the therapy of human disease and review the major studies that have laid the groundwork for its current clinical indication. CONCLUSION: The use of azacitidine has changed the approach to the treatment of MDS and has resulted in improved outcomes for patients.

DrugBank Data that Cites this Article

Drugs

Azacitidine

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Azacitidine	DNA	Nucleotide	Humans	Yes	Other	Details
Azacitidine	DNA (cytosine-5)-methyltransferase 1	Protein	Humans	Yes	Inhibitor	Details